Decrease in the effectiveness of valproic acid against the background of antibacterial therapy with imipenem/cilastatin in pediatric practice: A case report

A clinical case of the co-medication of valproic acid and cilastatin/imipenem in a 17-year-old girl with generalized tonic-clonic seizures is described. As an antiepileptic therapy, the child was prescribed valproic acid, the concentration of which in the blood plasma was more than 80 µg/ml, and seizures were not observed during this therapy. At the same time, due to the developed pneumonia, the girl was imipenem/cilastatin prescribed. Co-medication of drugs led to a decrease in the concentration of valproic acid in the blood plasma less than 50 µg/ ml, relapse of epileptic seizures was noted. Correction of antiepileptic therapy with phenobarbital did not lead to the seizure control. The removal of imipenem/ cilastatin contributed to the increase in the concentration of valproic acid in blood plasma above 50 µg/ ml, which corresponds to the recommended therapeutic range. Within two weeks after discontinuation of imipenem/ cilastatin, the concentration of valproic acid reached values as close as possible to the values before the start of antibiotic therapy. The authors of the article concluded that it is necessary to conduct therapeutic drug monitoring in children receiving valproic acid and imipenem/ cilastatin (antibiotic of carbapenem group), based on the known mechanisms of pharmacokinetic interaction.

1. Fine A., Wirrell E.C. Seizures in children. Pediatr. Rev. 2020;41(7):321–347. doi: 10.1542/pir.20190134

2. Muthaffar O.Y., Almahmudi S.M., Alrabghi M.O., Bin Mahfouz M.M., Alfawaz N.S. Valproic acid for children below 2 years of age with epilepsy. Neurosciences (Riyadh). 2021;26(4):357–365. doi: 10.17712/nsj.2021.4.20210075

3. Al-Quteimat O., Laila A. Valproate interaction with carbapenems: review and recommendations. Hosp. Pharm. 2020;55(3):181–187. doi: 10.1177/0018578719831974

4. Williams J.H., Jayaraman B., Swoboda K.J., Barrett J.S. Population pharmacokinetics of valproic acid in pediatric patients with epilepsy: considerations for dosing spinal muscular atrophy patients. J. Clin. Pharmacol. 2012;52(11):1676–1688. doi: 10.1177/0091270011428138

5. Rahman M., Nguyen H. Valproic acid. StatPearls [Internet]. Available from: https://www.ncbi.nlm.nih.gov/books/NBK559112

6. Ghodke-Puranik Y., Thorn C.F., Lamba J.K., Leeder J.S., Song W., Birnbaum A.K., Altman R.B., Klein T.E. Valproic acid pathway: pharmacokinetics and pharmacodynamics. Pharmacogenet. Genomics. 2013;23(4):236–241. doi: 10.1097/FPC.0b013e32835ea0b2

7. Lheureux P.E., Penaloza A., Zahir S., Gris M. Science review: carnitine in the treatment of valproic acid-induced toxicity – what is the evidence? Crit. Care. 2005;9(5):431–440. doi: 10.1186/cc3742

8. Xu S., Chen Y., Zhao M., Guo Y., Wang Z., Zhao L. Population pharmacokinetics of valproic acid in epileptic children: Effects of clinical and genetic factors. Eur. J. Pharm. Sci. 2018;122:170–178. doi: 10.1016/j.ejps.2018.06.033

9. Monostory K., Nagy A., Tóth K., Bűdi T., Kiss Á., Déri M., Csukly G. Relevance of CYP2C9 function in valproate therapy. Curr. Neuropharmacol. 2019;17(1):99–106. doi: 10.2174/1570159X15666171109143654

10. Levy R.H., Koch K.M. Drug interactions with valproic acid. Drugs. 1982;24(6):543–56. doi: 10.2165/00003495-198224060-00004

11. Chen I.L., Lee C.H., Hsiao S.C., Shih F.Y. Interactions between carbapenems and valproic acid among the patients in the intensive care units. J. Crit. Care. 2021;62:151–156. doi: 10.1016/j.jcrc.2020.12.005

12. Lee M.C., Sun Y.H., Lee C.H., Wu A.J., Wu T.W. Interaction between valproic acid and carbapenems: Case series and literature review. Tzu Chi Medical Journal. 2012;24(2):80–84. doi: 10.1016/j.tcmj.2012.02.008

13. Thomas C., Priano J., Smith T.L. Meropenem as an antidote for intentional valproic acid overdose. Am. J. Emerg. Med. 2020;38(3), 690.e1–690.e2. doi: 10.1016/j.ajem.2019.09.011

14. Sanivarapu R., Sharma R., Akella J. Thinking out of the box: management of valproic acid toxicity with carbapenems. BMJ Case Rep. 2021;14(3):e240140. doi: 10.1136/bcr-2020-240140

15. Smolders E.J., Ter Heine R., Natsch S., Kramers K. Meropenem to treat valproic acid intoxication. Ther. Drug. Monit. 2022;44(3):359–362. doi: 10.1097/FTD.0000000000000973

16. Park M.K., Lim K.S., Kim T.E., Han H.K., Yi S.J., Shin K.H., Cho J.Y., Shin S.G., Jang I.J., Yu K.S. Reduced valproic acid serum concentrations due to drug interactions with carbapenem antibiotics: overview of 6 cases. Ther. Drug. Monit. 2012;34(5):599–603. doi: 10.1097/FTD.0b013e318260f7b3